not for APRI, but for PTN for now, Femprox will need to get a partner deal in order to see a boost in share price, this could be a first step to that, but Femprox is for a different indication, arousal not desire, and will require lots of expensive trial work, femprox is still a long way off from an approval like this.
With the FDA, Sprout Pharmaceuticals developed a comprehensive Risk Evaluation and Mitigation Strategy (REMS) program, including prescriber and pharmacist certification, to ensure safe use of Addyi. Sprout has also committed to enhanced pharmacovigilance and Phase 4 studies to mitigate and further characterize the safety profile of Addyi.
Addyi is anticipated to be available by October 17, 2015. For more information and Prescribing Information, visit www.addyi.com.
Please see Indication and Important Safety Information below.
Conference Call
Sprout Pharmaceuticals will host a teleconference on Wednesday, August 19th, at 9:30 a.m. EDT. The teleconference is accessible by dialing 888-632-3383, with international callers dialing 785-424-1676 |
